BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34263930)

  • 1. Expected individual benefit of prophylactic platelet transfusions in hemato-oncology patients based on bleeding risks.
    Cornelissen LL; Caram-Deelder C; Fustolo-Gunnink SF; Groenwold RHH; Stanworth SJ; Zwaginga JJ; van der Bom JG
    Transfusion; 2021 Sep; 61(9):2578-2587. PubMed ID: 34263930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
    Estcourt LJ; Stanworth S; Doree C; Trivella M; Hopewell S; Blanco P; Murphy MF
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010984. PubMed ID: 26505729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
    Estcourt LJ; Stanworth SJ; Doree C; Hopewell S; Trivella M; Murphy MF
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010983. PubMed ID: 26576687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
    Stanworth SJ; Estcourt LJ; Powter G; Kahan BC; Dyer C; Choo L; Bakrania L; Llewelyn C; Littlewood T; Soutar R; Norfolk D; Copplestone A; Smith N; Kerr P; Jones G; Raj K; Westerman DA; Szer J; Jackson N; Bardy PG; Plews D; Lyons S; Bielby L; Wood EM; Murphy MF;
    N Engl J Med; 2013 May; 368(19):1771-80. PubMed ID: 23656642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia.
    Vinholt PJ; Alnor A; Nybo M; Hvas AM
    Platelets; 2016 Sep; 27(6):547-54. PubMed ID: 27025360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.
    Desborough M; Estcourt LJ; Doree C; Trivella M; Hopewell S; Stanworth SJ; Murphy MF
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010982. PubMed ID: 27548292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial.
    Stanworth SJ; Estcourt LJ; Llewelyn CA; Murphy MF; Wood EM;
    Transfusion; 2014 Oct; 54(10):2385-93. PubMed ID: 24724863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.
    Stanworth SJ; Dyer C; Choo L; Bakrania L; Copplestone A; Llewelyn C; Norfolk D; Powter G; Littlewood T; Wood EM; Murphy MF;
    Transfus Med Rev; 2010 Jul; 24(3):163-71. PubMed ID: 20656185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis.
    Stanworth SJ; Hudson CL; Estcourt LJ; Johnson RJ; Wood EM;
    Haematologica; 2015 Jun; 100(6):740-7. PubMed ID: 25795717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic platelet transfusions prior to surgery for people with a low platelet count.
    Estcourt LJ; Malouf R; Doree C; Trivella M; Hopewell S; Birchall J
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012779. PubMed ID: 30221749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
    Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
    Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions.
    Friedmann AM; Sengul H; Lehmann H; Schwartz C; Goodman S
    Transfus Med Rev; 2002 Jan; 16(1):34-45. PubMed ID: 11788928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non-cardiac surgery or invasive procedures.
    Huber J; Stanworth SJ; Doree C; Fortin PM; Trivella M; Brunskill SJ; Hopewell S; Wilkinson KL; Estcourt LJ
    Cochrane Database Syst Rev; 2019 Nov; 11(11):CD012745. PubMed ID: 31778223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
    Desborough M; Hadjinicolaou AV; Chaimani A; Trivella M; Vyas P; Doree C; Hopewell S; Stanworth SJ; Estcourt LJ
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012055. PubMed ID: 27797129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose of prophylactic platelet transfusions and prevention of hemorrhage.
    Slichter SJ; Kaufman RM; Assmann SF; McCullough J; Triulzi DJ; Strauss RG; Gernsheimer TB; Ness PM; Brecher ME; Josephson CD; Konkle BA; Woodson RD; Ortel TL; Hillyer CD; Skerrett DL; McCrae KR; Sloan SR; Uhl L; George JN; Aquino VM; Manno CS; McFarland JG; Hess JR; Leissinger C; Granger S
    N Engl J Med; 2010 Feb; 362(7):600-13. PubMed ID: 20164484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.
    Estcourt LJ; Desborough M; Brunskill SJ; Doree C; Hopewell S; Murphy MF; Stanworth SJ
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009733. PubMed ID: 26978005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen-reduced platelets for the prevention of bleeding.
    Estcourt LJ; Malouf R; Hopewell S; Trivella M; Doree C; Stanworth SJ; Murphy MF
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD009072. PubMed ID: 28756627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.